Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
Moreno
Ana
A
Pérez-Elías
María J
MJ
Casado
José L
JL
Fortún
Jesús
J
Bárcena
Rafael
R
Quereda
Carmen
C
Del Campo
Santos
S
Gutiérrez
Carmen
C
Pastor
Oscar
O
Nuño
Javier
J
Fernandez
Ana
A
Moreno
Santiago
S
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000379:methods*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000378:metabolism; D000068898:Raltegravir Potassium; D013997:Time Factors; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D007166:Immunosuppressive Agents; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium